Weekly Spotlight - 03.10.24

In the News

New Treatment Shows Promise for Myasthenia Gravis Patients

A recent Phase 3 clinical trial has shown that a medication called inebilizumab can significantly reduce the severity of symptoms in patients with generalized myasthenia gravis (gMG). This condition causes muscle weakness and fatigue. The trial results are promising, suggesting that inebilizumab could become an important treatment option for those living with gMG.

New MG Medications Not Recommended by PBAC, But Advocacy Efforts Continue

The Pharmaceutical Benefits Advisory Committee (PBAC) recently reviewed two new medications for myasthenia gravis, Raviluzimab and Zilucoplan. Unfortunately, both medications were not recommended for approval. Despite this setback, the PBAC acknowledged the urgent need for effective treatments for generalized myasthenia gravis (gMG). Advocacy efforts are ongoing to ensure that patients receive the best possible care and treatment options in the future.

ARGX-119 may be an antibody therapy for MuSK-MG

ARGX-119, an antibody therapy, shows promise for MuSK-associated myasthenia gravis (MG). In mice, it prevented disease onset and reversed symptoms post-onset. This targeted approach could offer a more effective alternative to general immunosuppression, potentially benefiting other neuromuscular diseases as well. Further research is needed for clinical application.

MGFA Awards $330,000 in Research Grants to Advance Myasthenia Gravis Research

The Myasthenia Gravis Foundation of America (MGFA) awarded $330,000 in research grants to three scientists from Duke, Yale, and Uppsala Universities. These grants support early-stage research on autoimmunity and biomarkers. MGFA's rigorous review process aligns with NIH standards, ensuring high-quality, impactful scientific projects.

Living with Myasthenia Gravis: A Journey of Resilience and Hope

Kathalina Nguyen, a 26-year-old emergency nurse, shares her journey with myasthenia gravis, an autoimmune neuromuscular disease. Diagnosed in October 2023, she recounts her initial symptoms, including a peculiar smile and difficulty speaking, which she initially dismissed. Her condition worsened, leading to double vision and a droopy eyelid, prompting a series of medical consultations and tests. Eventually, she was diagnosed and began treatment with Mestinon, which provided some relief.

Despite the challenges, Kathalina's participation in a clinical trial has significantly improved her symptoms, allowing her to return to her beloved nursing career and continue her studies. Her story underscores the importance of perseverance and the potential of clinical trials in advancing treatment options. She remains optimistic and committed to raising awareness about myasthenia gravis, encouraging others to explore various treatment avenues and never lose hope